Research programme: toll-like 7 receptor agonists - Sumitomo Dainippon Pharma/AstraZeneca

Drug Profile

Research programme: toll-like 7 receptor agonists - Sumitomo Dainippon Pharma/AstraZeneca

Alternative Names: Antedrug toll-like receptor 7 (TLR7) agonists - Dainippon Sumitomo Pharma/AstraZeneca; AZ12441970

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer AstraZeneca; Sumitomo Dainippon Pharma
  • Class
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Respiratory tract disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in Japan
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in United Kingdom
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top